Plasma and bronchoalveolar lavage fluid levels of endothelin-1 in patients with chronic obstructive pulmonary disease and pulmonary hypertension

Basit Öğe Kaydı
dc.contributor.authorBacakoglu, F
dc.contributor.authorAtasever, A
dc.contributor.authorOzhan, MH
dc.contributor.authorGurgun, C
dc.contributor.authorOzkilic, H
dc.contributor.authorGuzelant, A
dc.date.accessioned2019-10-27T18:42:06Z
dc.date.available2019-10-27T18:42:06Z
dc.date.issued2003
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Secondary pulmonary hypertension (PH) and cor pulmonale are the major clinical cardiovascular complications affecting prognosis in patients with chronic obstructive pulmonary disease (COPD). It is also known that endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by the pulmonary vascular endothelium, and ET-1 may be implicated in the pathogenesis of PH. Objectives: The purpose of this study was to investigate the presence of ET-1 in patients with COPD and to assess the correlation of ET-1 levels in the plasma and bronchoalveolar lavage (BAL) fluid (BALF) in COPD patients with or without PH. Methods: Twenty-two patients with COPD and 15 healthy controls were enrolled in the study. Peripheral venous blood samples were collected in all patients and controls. BAL was obtained in COPD patients, and ET-1 levels were measured by radioimmunoassay in all plasma and BALF samples. Results: Plasma ET-1 levels were 2.46 +/- 0.55 and 1.70 +/- 0.42 pmol/dl in patients with COPD and controls, respectively (p < 0.0001). Sixteen of the 22 patients with COPD (73%) had PH established by echocardiography. The ET-1 level in these patients amounted to 2.59 +/- 0.50 pmol/dl, and it was 2.10 +/- 0.54 pmol/dl in 6 patients with COPD without PH. In COPD patients with and without PH, BALF ET-1 levels were 0.19 +/- 0.08 and 0.24 +/- 0.01 pmol/dl, respectively (p > 0.05). Conclusions: These results suggest that ET-1 is detectable in both the peripheral blood and BALF of COPD patients, but the levels do not statistically differ between patients with and without PH. Copyright (C) 2003 S. Karger AG, Basel.en_US
dc.identifier.doi10.1159/000075204en_US
dc.identifier.endpage599en_US
dc.identifier.issn0025-7931
dc.identifier.issn1423-0356
dc.identifier.issue6en_US
dc.identifier.pmid14732789en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage594en_US
dc.identifier.urihttps://doi.org/10.1159/000075204
dc.identifier.urihttps://hdl.handle.net/11454/37084
dc.identifier.volume70en_US
dc.identifier.wosWOS:000188119700007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofRespirationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbronchoalveolar lavageen_US
dc.subjectchronic obstructive pulmonary disease endothelin-1en_US
dc.subjectplasmaen_US
dc.subjectpulmonary hypertensionen_US
dc.titlePlasma and bronchoalveolar lavage fluid levels of endothelin-1 in patients with chronic obstructive pulmonary disease and pulmonary hypertensionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu